Combination of such two inhibitors has also been investigated in phase II clinical trial (NCT03392246) in EGFR mutant NSCLC cancer, and preliminary signal of activity were seen in phase I trial in a subgroup of patient, negative for MET expression45. This evidence concerns the gene MET and cancer.